Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
L Valeyrie, S Bastuji-Garin, J Revuz, N Bachot… - Journal of the American …, 2003 - Elsevier
Background: Imatinib is a new major treatment in chronic myeloid leukemia. Objective: To
study the cutaneous reactions induced by imatinib. Methods: All inpatients and outpatients
with Philadelphia chromosome-positive leukemia treated by imatinib were included in this
prospective study. Clinical features, pathologic findings, evolution of each case, and
analysis of potential risk factors were recorded. Results: A total of 54 patients were included,
48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 …
study the cutaneous reactions induced by imatinib. Methods: All inpatients and outpatients
with Philadelphia chromosome-positive leukemia treated by imatinib were included in this
prospective study. Clinical features, pathologic findings, evolution of each case, and
analysis of potential risk factors were recorded. Results: A total of 54 patients were included,
48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 …